High Sstr2 expression is also a defining feature in many neuroendocrine tumors, and as such Sstr2 agonists are often used to suppress the excess hormone secretion that is a common, debilitating feature in these tumors (1, 2, 3, 4, 5). Here, SSTR2 is linked to neuroendocrine neoplasm.